Binder Groesswang has advised microbiome technology R&D company Biome Diagnostics on its investment round with Uniqa Group company SanusX. Schoenherr reportedly advised the investors.
Sobczynski and Partners and MKS Partners Advise on THC Acquisition of Dental Medicenter
Sobczynski and Partners has advised Tar Heel Capital on the acquisition – on behalf of its Dentity dental chain – of a 70% stake in Warsaw's Dental Medicenter. Michaliszyn Koska Saluda advised the Dental Medicenter shareholders.
Gessel Advises Pure Biologics on PLN 12 Million Investment from ACRX Investments
Gessel has advised Wroclaw-based biopharmaceutical company Pure Biologics on receiving a PLN 12 million investment from ACRX Investments Limited.
Competition and Regulatory Challenges in the CEE Pharma Sector - Part 2: Regulatory Hot Topics and Market Access Challenges in CEE and War-Related Changes in Ukraine
Global law firm Baker McKenzie organized a competition and regulatory conference for pharma in Central and Eastern Europe (CEE) in Warsaw. During the conference, Baker McKenzie experts highlighted the hot topics of recent developments in EU Competition Law and Pharmaceutical Regulation that have direct effect on companies in the pharma and life sciences sector, discussing practical and pragmatic solutions with special regard to regional aspects in CEE in two round tables. The second one looked at regulatory hot topics and market access challenges in CEE and war-related changes in Ukraine.
Wardynski & Partners Appoints Six New Partners
Joanna Krakowiak, Jakub Macek, Wojciech Marszalkowski, Adam Pawlisz, Lukasz Sliwinski, and Maciej Zych make Contract Partner at Wardynski & Partners in Poland.
Competition and Regulatory Challenges in the CEE Pharma Sector - Part 1: Recent Competition Law Developments
Global law firm Baker McKenzie organized a competition and regulatory conference for pharma in Central and Eastern Europe (CEE) in Warsaw. During the conference, Baker McKenzie experts highlighted the hot topics of recent developments in EU Competition Law and Pharmaceutical Regulation that have direct effect on companies in the pharma and life sciences sector, discussing practical and pragmatic solutions with special regard to regional aspects in CEE in two round tables. The first one looked at recent competition law developments.
ODI Law and Wolf Theiss Advise on SHS Capital EUR 18 Million Investment in MESI Medical
ODI Law has advised Slovenian diagnostic company MESI on the EUR 18 million investment received from SHS Capital's SHS VI Healthcare Investments fund. Wolf Theiss advised the investor.